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FilGAPFilamin A (FlnA) is a ubiquitous actin binding protein which anchors various transmembrane proteins to the cell
cytoskeleton and provides a scaffold to many cytoplasmic signaling proteins involved in actin cytoskeleton re-
modeling in response tomechanical stress and cytokines stimulation. Although the vast majority of FlnA binding
partners interact with the carboxy-terminal immunoglobulin like (Igl) repeats of FlnA, little is known on the role
of the amino-N-terminal repeats. Here, using cardiac mitral valvular dystrophy associated FlnA–G288R and
P637Q mutations located in the N-terminal Igl repeat 1 and 4 respectively as a model, we identiﬁed a new role
of FlnA N-terminal repeats in small Rho-GTPases regulation. Using FlnA-deﬁcient melanoma and HT1080 cell
lines as expression systemswe showed that FlnAmutations reduce cell spreading and migration capacities. Fur-
thermore, we deﬁned a signaling network in which FlnA mutations alter the balance between RhoA and Rac1
GTPases activities in favor of RhoA andprovided evidences for a role of the Rac1 speciﬁc GTPase activating protein
FilGAP in this process. Together our work ascribed a new role to the N-terminal repeats of FlnA in Small GTPases
regulation and supports a conceptual framework for the role of FlnAmutations in cardiac valve diseases centered
around signaling molecules regulating cellular actin cytoskeleton in response to mechanical stress.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The Filamin gene family consists of three highly related homologous
proteins produced from three separate gene loci. Filamin's A (alpha), B
(beta), and C (gamma) share similar molecular organization consisting
of a conserved N-terminal actin binding region followed by 24
immunoglobulin-like (Igl) repeated domains among which the 24th is
involved in non-covalent protein dimerization [1–3]. Filamin A (FlnA)
is the ﬁrst actin ﬁlament cross-linking protein identiﬁed in non-muscle
cells and organizes actin ﬁlaments in orthogonal networks to stabilize
the cellular actin cortex [4].
Many previous studies deﬁned central roles for FlnA in mechano-
protection, cell adhesion, spreading andmigration [1–3,5,6], cell survival,
morphogenesis, wound healing and human disease pathogenesis [6,7].
In addition to its interactions with actin, FlnA functions also depend on. Duval),
ahoo.fr (T. Le Tourneau),
.R. Markwald),
chu-nantes.fr (V. Probst),
RTNERS.ORG (R. Levine),
tes.fr (J. Merot).
ights reserved.its cell and tissue-speciﬁc association with numerous binding partners.
To date, over 90 FlnA-binding partners have been identiﬁed many of
which participate in the regulation of intracellular signaling pathways
to promote cytoskeleton remodeling. Some of these partners include
small GTPases and their regulators, integrins receptors and associated
kinases [3,8]. Although the structural features underlying the binding
of speciﬁc partners to the C-terminal Igl repeats are becoming better un-
derstood, there is a paucity of information regarding functional determi-
nation of theN-terminal FlnA region forwhich fewprotein partners have
been identiﬁed [9–11]. One that does interact with the 3rd Igl repeat of
N-terminal FlnA is R-Ras which is known to participate in the mainte-
nance of endothelial cell barrier function [12,13]. The intermediate ﬁla-
ment protein vimentin and PKCε which participate in cell adhesion
also interact with FlnA 1–8 repeats whereas the tyrosine kinase Syk
binds the ﬁfth repeat of FlnA and participates in platelet activation
[11,14,15].
Human mutations in the FLNA gene cause a wide spectrum of
congenital anomalies including: periventricular heterotopy (PVH),
Melnick–Needles syndrome (MNS), otopalatodigital syndrome (OPD),
and myxomatous valvular dystopohy [16–18]. Causal FlnA mutations
that contribute to each of these diseases are found throughout the
encoded protein, further suggesting tissue-speciﬁc function of the
affected FlnA subdomains. Whereas mutations that cause PVH, MNS,
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myxomatous valvular dystrophy is caused by mutations in the poorly
studied N-terminus. In the present study, we have analyzed the func-
tional effects of two N-terminal mutations (FlnA–G288R and P637Q)
that cause X-linked myxomatous valvular dystrophy (XMVD) [19,20].
We demonstrate that these mutations alter the balance of the small
GTPases, RhoA and Rac1, and alter their potential to remodel the actin
cytoskeleton during cell adhesion, spreading andmigration and present
candidate mechanisms bywhich this may contribute to the pathogene-
sis of mitral valve prolapse.
2. Materials and methods
2.1. Reagents
Polyclonal antibodies for GAPDH (1:10,000); RhoA (1:500) and
HRP-conjugated antibodies (1:10 000) were purchased from Santa
Cruz. Alexa Fluor 488 and Alexa Fluor 594 were purchased from Life
Technologies. Monoclonal antibodies were purchased from Chemicon
(anti-ﬁlamin A, 1:1000), BD Transduction Laboratories (anti-Rac1,
1:500), Sigma-Aldrich (FilGAP, 1:250; ß-actin, 1:500), Roche (anti-HA,
1:1000), Clontech (GFP, 1:1000). Y27632 andNSC23766were purchased
from Santa Cruz and human plasma Fibronectin from Sigma-Aldrich.
2.2. Cell culture, stable cell lines and transfection
The FlnA-deﬁcient human melanoma cell line (M2) and the stably
FlnA–WT transfected subclone (A7) were obtained fromDr. F Nakamura
(Harvard University, Cambridge, MA) and shRNA knockdown HT1080
from Dr Calderwood (Yale University, New Haven, USA) [21]. M2 cells
were cultured in minimum essential mediumα (MEMα) supplemented
with 8% newborn calf serum, 2% fetal calf serum (FCS) and HT1080 cells
in DMEM supplementedwith 10% FCS and 2 μg/ml puromycin. To estab-
lish stable cell lines expressing FlnA–WT, G288R and P637Q, M2 cells
were transfected with pcDNA3–FlnA–WT, pcDNA3–FlnA–G288R and
pcDNA3–FlnA–P637Q plasmids using Fugene6 (Roche-Applied Science).
The clones were selected and then grown in the presence of G418
(800 μg/ml for selection and 200 μg/ml for routine culture).
2.3. Plasmid and SiRNA
FlnA–WT cDNA was cloned in pcDNA3 and G288R or P637Q
mutations introduced using QuikChange® Site-Directed Mutagenesis
Kit (Stratagene). GFP tagged shRNA resistant FlnA–WT cDNA was a
kind gift of Dr D Calderwood (Yale University, New Haven CT, USA) in
which G288R and P637Q were introduced by site directed mutagenesis
[21]. The pCMV5HA–FilGAPWTwas a gift of Dr YasutakaOhta (Division
of Cell Biology, Kitasato University, Kitasato, Japan). To deplete endoge-
nous FilGAP, siRNA oligonucleotide duplexes targeting the sequence
5′-AAGATAGAGTATGAGTCCAGGATAA-3′ (nt 1975–1999 of FilGAP)
were used [22]. Control siRNA duplexes targeting GFP were used (sense
5′-GCAAGCUGACCCUGAAGUUCAU-3′, antisense 5′-GAACUUCAGGGU
CAGCUUGCCG-3′). The cells were transfected according to the suppliers'
guidelines (Eurogentec) and used 48 hours post transfection.
2.4. Adhesion and spreading assays
In adhesion assays, 2.5 × 104 cells were seeded on coverslips coated
with 25 μg/ml ﬁbronectin and incubated at 37 °C for 45 min followed
by two consecutive PBSwashes. Adherent cells were ﬁxedwith 2%para-
formaldehyde (PFA), stained with DAPI and counted in 10 ﬁelds under
microscopic observation (10× objective). Alternatively, the impedance
measurement technology of the xCELLigence system was used to mon-
itor cell adhesion and spreading [23]. 1 × 104 cells per well were plated
into 96-wells E-Plates (Roche Diagnostics, GmbH), placed on the Real
Time Cell Analyzer and incubated at 37 °C in a 5% CO2 incubator. Celladhesion and spreading were measured as the changes in the electrical
impedance between the microelectrodes lining the bottom of the wells
and expressed as a Cell Index (CI) according to themanufacturer's guide-
lines. For inhibitor assays, Y27632 (10 μm) and NSC23766 (10 μm)
were added to the culture medium when the cells were seeded in the
96-wells E-Plate. Impedance measurements were taken every 1 min
for 3 hours. The slope of CI changes (dCI/dt) was calculated between
t30min and t1h30min.
2.5. Migration assays: wound healing and “Transwell” assays
In wound healing assays, conﬂuent cell monolayers were scratched
with a pipette tip, washed with phosphate-buffered saline (PBS) and
cell migration monitored using a Leica DMI6000B microscope equipped
for time-lapse video microscopy. Wound closure was monitored for
24–28 h on 3 ﬁelds per well and the data are presented as % of closure
of FlnA–WT cells monolayer wound closure at t = 24 hrs. Transwell mi-
gration assays were performed using 8 μmpore size bottom ﬁlter cham-
bers (Corning, Costar Corp). 5 × 104 cells were serum-starved overnight
and seeded in 200 μl of serum-freeMEM into the upper chamber,where-
as the lower compartment was ﬁlled withMEM supplementedwith 10%
serum. After 8 hours at 37 °C, cells remaining on the upper surface of the
ﬁlter werewiped outwith a cotton swab, and the cells that hadmigrated
on the lower surface of the ﬁlter were ﬁxed, stained with DAPI and
counted in ten microscopic ﬁelds.
2.6. Immunoﬂuorescence microscopy
Cells were seeded on coverslips, washed three times with PBS and
subsequently ﬁxed in 2% PFA for 15 min, permeabilized with 0.1% Tri-
ton X-100, incubated with primary antibodies (dilution: 1/1000) in 1%
of bovine serum albumin for 1 h and then with Alexa 594 or 488 conju-
gated secondary antibody for 1 h. Rhodamine conjugated-phalloidin
(1 μg/ml, Invitrogen)was added for 20 min to detect actin cytoskeleton
and nuclei were counterstained with DAPI for 10 min. Coverslips were
mounted in Prolongold (Invitrogen) and observed on a Zeiss Axiovert
microscope.
2.7. Co-immunoprecipitation and immunoblotting
Cells transfected with FilGAP-HA were lysed in NETF buffer
containing: 100 mM NaCl, 2 mM EGTA, 50 mM Tris pH 7.5, 50 mM NaF,
1% NP-40, 1 mM PMSF, 1 mM Na3VO4, 1× protease inhibitor cocktail
(Roche) and lysates clariﬁed by centrifugation (15,000 ×g for 15 min at
4 °C). The cell lysates (500 μg) were incubated with 6 μg of anti-HA for
2 h at 4 °C and thenwith 30 μl of proteinA conjugated beads (Dynabeads,
Invitrogen) for 1 h at 4 °C. The immunoprecipitates were washed four
times with NETF buffer and separated by SDS-PAGE transferred to nitro-
cellulose membrane (Bio-Rad Transblot). Immunoblots probed with ap-
propriate antibodies and revealed using enhanced chemiluminescence
kit (GE Healthcare). Chemiluminescence signals were quantiﬁed using
an Imager system (Roche Diagnostic) and the data normalized with re-
spect to GAPDH.
2.8. Glutathione-S-transferase (GST) protein puriﬁcation andGST pull-down
GST–Rothekin (GST–RTK) or GST–Crib containing the Cdc42/Rac
Interactive Binding (Crib) region of p21 activated kinase were pro-
duced in Bl21 E. coli treated overnight with 1 mM IPTG at 25 °C.
The GST–Rac1–Q61L fusion protein used to analyze FilGAP activity
in a Rac1–GAP activity pull down assay, was a kind gift of Dr C.
Guilluy and K Burridge (Institut du Thorax, Nantes, France) [24]. The
GST-fusion proteins were puriﬁed using Glutathione Agarose 4B beads
(Macherey-Nagel). Cells grown for 2–4 hrs after seeding were lysed in
NETF buffer. The cell lysates were centrifuged at 15,000 ×g for 15 min
at 4 °C. 500 μg of cleared cell lysates were incubated with GST-tagged
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washed four times with cell lysis buffer and bound proteins separated
by SDS-PAGE. Bound Rac1 and RhoAwere detected by immunoblotting
as describe above. In Rac1–GAP activity assay, FlnA–WT, G288R and
P637Q stable cell lines were transfected with FilGAP–HA and pulled
down FilGAP quantiﬁed by western blotting.A
B
C
Fig. 1. Screening of stable melanoma cell lines expressing FlnA-WT, G288R or P637Q. A. Schem
followed by 24 Igl repeats. The Igl repeats are interrupted by two hinges regions (in red). FlnA
and 4, respectively. B. Western blot analysis of total cell extracts (25 μg) from original M2 (Fln
pression ratio comparable to the original A7 cell line were conserved. C. Selection of FlnA stab
and those established in the present study FlnA–WT (upper right), G288R and P637Q (lower i
were selected and the arrows indicate the few non-expressing cells in mutant FlnA clones. The2.9. Statistical analysis
Each assay presented here was performed at least three times.
Graphs depict mean values ± SEM of sample size n. Images presented
here are representative of each sample analyzed. Data were analyzed
using Prism (GraphPad Software) and P-values were generated usingatic representation of human Filamin A. The N-terminal actin-binding domain (ABD) is
–G288R and P637Q mutations associated to dystrophy valvular are located on repeats 1
A-deﬁcient), A7, FlnA–WT, G288R and P637Q cell lines. Only clones with a FlnA/actin ex-
le cell lines: Immunostaining of the original FlnA–WT expressing cell line A7 (upper left)
mages) (anti-FlnA antibody, green). Only clones exhibiting over 80% of FlnA positive cells
nuclei were stained with DAPI (blue) (scale bar: 20 μm).
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3. Results
3.1. FlnA mutants restore mesenchymal morphology of FlnA deﬁcient
melanoma cells
The FlnA-deﬁcientmelanoma cell line (M2) is a tractable cell line for
analyzing the function of the two FlnA mutations (G288R and P637Q)
and is commonly used as a model to study FlnA effects on cell behavior
(Fig. 1A) [25]. We thus established cell lines stably expressing
FlnA–G288R or FlnA–P637Q. In addition, to avoid any bias linked to
the use of a FlnA plasmid construct different from that used to establish
the original FlnA–WT-reconstituted cell line (A7), we also established
FlnA–WT stable cell lines [25]. As illustrated in Fig. 1B and C, only clones
exhibiting over 80% of FlnA positive cells and a FlnA/ß-actin ratio com-
parable to that of the wild-type melanoma cell line (A7) were selected.
Three clones of each FlnA construct were ampliﬁed and further ana-
lyzed. They gave similar results in the different experiments made
throughout the study and the data were thus pooled together. Impor-
tantly, the FlnA–WT clones produced and studied here were indistin-
guishable from the original A7 clone.
Previous studies established the critical role of FlnA in the orga-
nization of the cortical actin network in M2 cells [8]. Speciﬁcally,
FlnA-deﬁcient M2 cells exhibited an amoeboid morphology with a
prolonged surface blebbing when plated on culture dishes (6 hrs after
plating, see arrows in Fig. 2A). On the contrary, neither A7, FlnA–WT,
G288R nor P637Q cells exhibited blebs during spreading (Fig. 2A). All
the FlnA expressing cells exhibited a mesenchymal-like morphology
with cellular protrusions at their periphery. Nevertheless, FlnA–G288R
and P637Q expressing cells were smaller than A7 and FlnA–WT cells,
both during spreading (6 hours) and at “steady” state (Fig. 2A and B,
respectively). Of note, FlnA–WT expressing cells developed more and
larger lamellipodia like structures during spreading than G288R and
P637Q cells (see arrowheads in Fig. 2A and right-hand histogram in
2B). These observations suggested that actin organization, when com-
pared to that of null cells, was at least partially restored by FlnAmutants
during the active remodeling phase of cell spreading. This notion was
further corroborated by adhesion kinetic analysis (Xcelligence data
below). Also, FlnA localization was not signiﬁcantly modiﬁed by the
mutations either and remained co-localized with actin along the cell
plasma membranes (Fig. 2C).
To ascertain our observations were not limited to and dependant on
the melanoma cells used, another cell model was tested. shRNA FlnA
knockdown HT1080 cells were transiently transfected with GFP tagged
shRNA-resistant FlnA–WT, G288R and P637Q constructs. As illustrated
in Fig. 3A, transient transfection of shRNA resistant ﬁlamins restored
their expression in HT1080 KO cells. Importantly, as observed in mela-
noma cells, FlnA–WT transfected cells were larger than mutant FlnA
cells during the spreading phase. Also, large lamellipodia were readily
observed in FlnA–WT cells and seldom in FlnA–G288R and P637Q
mutants (right-hand histogram in Fig. 3B).
Together these data suggest that although the ability of FlnA
to organize actin cytoskeleton is maintained in FlnA–G288R and
P637Q mutants, the latter may affect actin network during spread-
ing. Because actin dynamics are intimately associated with cell adhe-
sion to a substratum and migration, these properties were analyzed
in details.
3.2. FlnA mutations affect cell adhesion and migration capacities
To investigate cell adhesion capacities stably transfected melanoma
cells were allowed to adhere for 45 min on ﬁbronectin coated coverslips,
the non-adherent cells were then washed away and adherent cells were
counted. As shown in Fig. 4A, whereas FlnA–WT expression signiﬁcantlyincreased the number of cells adhering in 45 min (x2.4 compared to
FlnA–KO (M2) P b 0.01 n = 4), FlnA mutations did not signiﬁcantly
improve adhesion when compared to the FlnA–KO cells (Fig. 4A).
Cell migration properties were evaluated in Ussing chambers and in
wound closure assays. As shown in Fig. 4B, cell migration through a po-
rous ﬁlter was signiﬁcantly increased in only FlnA–WT expressing cells
when subjected to a serum gradient (×2.2 P b 0.01 n = 3). Similarly,
only FlnA–WT cells were able to close a “scratch” made in a conﬂuent
cell monolayer within 24 hrs (Fig. 4C).
These data support a mechanism by which FlnA–G288R and P637Q
mutations do not signiﬁcantly affect actin organization and patterning,
but do affect overall cellmorphology, adhesion, andmigration capacities.
These data indicate a putative role for these mutations in the activation
and remodeling of the actin cytoskeleton. Because small GTPases of the
Rho family are key regulators of actin-remodeling reactions governing
cell adhesion, migration and morphology, we investigated the inﬂuence
of these FlnA mutations on RhoA and Rac1 GTPase activities.3.3. FlnA mutations affect the balance of RhoA–Rac1 activities during
spreading
In a ﬁrst step, we focused on the FlnA–P637Q mutations and
performed pull down experiments using GST–Rothekin (GST–RTK) or
GST–Cdc42/Rac Interactive Binding (GST–Crib) fusion proteins to eval-
uate RhoA and Rac1–GTPases activities, respectively. As illustrated in
Fig. 5A, Rac1 activity measured in FlnA–P637Q was reduced by more
than 50% with respect to that measured for FlnA–WT cells. Conversely,
RhoA activity was signiﬁcantly higher in FlnA–P637Q vs FlnA–WT cells
(Fig. 5B). To analyze the impact of these small GTPases activities on
the kinetics of cell adhesion and spreading, we used the impedance
measurement technology of the xCELLigence system. As illustrated in
Fig. 6A (left panel), thewild type FlnA “cell index” (CI) rapidly increased
after seeding the cells on the E-plate. However, and as expected from
the above data, the CI of FlnA–P637Q cells remained lower than that
of FlnA–WT cells throughout the experiments. Lower “steady state” CI
at 2 hours (before the cells started to divide) corroborated the smaller
size of FlnA–P637Q cells we observed (Fig. 2). Also, the slopes of
the curves were signiﬁcantly lower for P637Q vs FlnA–WT cells
(dCI/dt = 0.14 ± 0.02 CI/min and 0.27 ± 0.03 CI/min, **P b 0.01,
n = 4, respectively). Thiswas consistentwith the lower spreading capac-
ities of FlnA–P637Q cells and their lower Rac1 activities. In fact, treatment
with the Rac1 speciﬁc inhibitor NSC23766 (10 μM) altered the CI of FlnA–
WT cells but had no effect on FlnA–P637Q cells (Fig. 6A, left panel).
NSC23766 signiﬁcantly decreased the kinetics and the stationaryCI values
of FlnA–WT cells down to those of FlnA–P637Q cells. FlnA–WT dCI/dt de-
creased from 0.27 ± 0.03 CI/min (n = 4) to 0.18 ± 0.04 CI/min (n = 3,
P b 0.01) in the presence of 10 μM NSC23766. Values not signiﬁcantly
different from those of FlnA–P637Q cells in the presence and the absence
of the inhibitor (dCI/dt = 0.14 ± 0.03 CI/min (n = 3) and dCI/dt =
0.14 ± 0.02 CI/min; n = 4, respectively).
We then tested the effects of the Rho associated kinase inhibitor
(Y27632). In the presence of Y27632 (10 μM), FlnA–P637Q andWT ad-
hesion kinetics were undistinguishable (Fig. 6A, right panel) and both
cell lines spread much faster and to a higher extend than untreated
FlnA–WT cells (dCI/dt = 0.44 ± 0.07 CI/min and 0.49 ± 0.04 CI/min
n = 4non-signiﬁcant difference, for FlnA–P637Q andWT respectively).
Together these data are consistent with a higher RhoA/ROCK signaling
activity in FlnA–P637Q cells compared to FlnA–WT expressing cells,
which in turn reduces Rac1 activity. This is supported by microscopic
observations showing that treatment of FlnA–P637Q cells with
Y27632 rescued the cellular morphology and resulted in the de novo
formation of large lamellipodia like structures comparable to the WT
cells (Fig. 6B). Together, these data support a mechanism by which
FlnA–P637Q mutation causes deregulation of the RhoA–Rac1 balance
in favor of higher RhoA activity.
AB
C
Fig. 2. Filamin A mutations affect cell morphology and size. A. Differential interference contrast images of M2, A7, FlnA–WT, G288R and P637Q cell lines 6 hours after plating. Note the
presence of membrane blebs at the surface of FlnA deﬁcient M2 cells only (arrows). A7 and FlnA–WT cells exhibit large lamellipodia structures with membrane rufﬂes (arrow heads).
Scale bar is 10 μm B. Cells expressing FlnA–G288R and P637Q are smaller than FlnA–WT cells. Histograms indicate the area of the cells (μm2) grown for 6 hrs (left-hand) or 24 hrs
(middle). At least 100 cells were measured in 3 experiments. Right-hand histogram indicates the number of cells exhibiting lamellipodia 6 hrs after plating. Error bars show SEM,
***P b 0.001 versus FlnA–WT cells. C. Co-localization of FlnA (green) and actin (phalloidin labeling in red) in FlnA–WT, G288R and P637Q cell lines. Note FlnA immunostaining decorates
cell plasma membrane. Co-localization of actin and FlnA appears in yellow in the merged images (scale bar 10 μm).
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like FlnA–P637A cells, the same CI features and sensitivity to Rac1 and
ROCK inhibitors (NSC23766 and Y27632, Fig. 6C left and right panels,
respectively). Importantly, similar adhesion defects of mutant FlnA
expressing cells were also observed in shRNA FlnA-knockdown HT1080
cells using the xCELLigence system (Supplementary Fig. S1).3.4. FlnA FilGAP interactions are not affected by FlnA mutations
Previous studies demonstrated that the reciprocal balance of low
Rac1 activity by elevated RhoA/ROCK activity involves GTPase Activat-
ing Proteins (GAPs) like ARHGAP22 and a closely related Rac1-speciﬁc
GAP protein, FilGAP. FilGAP appeared as an interesting candidate
AB
Fig. 3. Filamin A mutations also affect morphology and size of HT1080 cells. A. Western blots of shRNA knockdown FlnA HT1080 cells (ﬁrst lane) and transfected with shRNA-resistant
FlnA–WT, G288R and P637Q. The blot probed with anti-FlnA shows FlnA expression is restored. B. Immuno-localization of GFP-tagged FlnAs using anti-GFP antibody (green) and actin
(phalloidin in red, scale bar 10 μm). Cells transfected with mutant FlnA–G288R and P637Q were smaller and exhibited less lamellipodia (left and right-hand histograms, respectively).
***P b 0.001 versus FlnA–WT transfected cells (n = 170 cells).
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ulated by ROCK phosphorylation [26,27]. Indeed, using speciﬁc siRNA to
silence FilGAP normalized spreading kinetics of both FlnA–P637Q and
G288R cells with respect to FlnA–WT cells. As illustrated in Fig. 7A,
siRNA treatment efﬁciently decreased FilGAP expression and FilGAP ex-
tinction had a small but signiﬁcant effect on the early adhesion kinetics
of FlnA–WT cells (dCI/dt = 0.23 ± 0.05 vs 0.22 ± 0.04 CI/min n = 4)
but had no effect on steady state CI. On the other hand, consistent
with the increased RhoA–ROCK signaling, FilGAP extinction clearlyincreased both adhesion kinetics and steady state CIs in FlnA–P637Q
(from dCI/dt = 0.12 ± 0.02 to 0.19 ± 0.04 CI/min, n = 4) and G288R
(from dCI/dt = 0.12 ± 0.02 to 0.22 ± 0.03 CI/min, n = 4) cells
(Fig. 7A, left and right panels respectively). Together these data suggest
that increased RhoA–ROCK pathway increases the GAP activity of
FilGAP which in turn contributes to imbalanced RhoA–Rac1 activities
in FlnA–P637Q and G288R cells and participates in the down regulation
of Rac1 during the process of cell attachment. In fact, this idea is consis-
tent with the result of Rac1 GAP activity pull down assays performed
A B
C
Fig. 4. Filamin Amutations impede cell adhesion andmigration. A. Percentage of adherent cells remaining on coverslips coatedwith ﬁbronectin after twowashes. Nuclei were stainedwith
DAPI and counted on 10 ﬁelds, n = 4, error bars show SEM, **P b 0.01 versus FlnA-KO cells. B. Percentage of cells seeded in the upper chamber of “transwell” ﬁlters that migrated over-
night in the lower chamber. The cells that had migrated were counted on 6 ﬁelds from three experiments n = 3, error bars show SEM, **P b 0.01 versus FlnA-KO (M2) cells. C. Typical
images of a wound made at the beginning (t0) and 24 hrs later (t24 h). Wound healing closure was calculated as the surface of the wound covered by the cells at t24 h and is expressed
in % in the histogram, n = 3, error bars show SEM, ***P b 0.001 versus FlnA–WT cells.
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shown in Fig. 7C, the amount of “active” FilGAP pulled down from mu-
tant FlnA cell lines more than doubled with respect to that isolated
from FlnA–WT cells.
4. Discussion
In the present study, we investigated the effects of FlnA–G288R and
P637Q mutations on the actin cytoskeleton organizing properties of
FlnA and showed that these point mutations deregulate the balance
between RhoA and Rac1 GTPase activities. Our data pointed to an unex-
pected and new role of the ﬁrst repeats of FlnA in cell morphology,
adhesion and migration capacities.
Since its discovery more than 30 years ago FlnAwas identiﬁed as an
actin binding protein and many studies established its crucial role in
actin cytoskeleton remodeling. However, its almost ubiquitous expres-
sion and its ability to homo- and hetero-multimerize with FlnB compli-
cated the functional analysis of mutant FlnAs in conventional in vitroexpressionmodel. In the absence of valvular cellularmodel easily acces-
sible to experimentation, we chose to use a FlnA-deﬁcient melanoma
cell line. Indeed, in their pioneering work Cunningham and colleagues
demonstrated that the FlnA deﬁcient cells (M2) used here, exhibit im-
paired locomotion and develop cell surface blebbing when they attach
to and spread on a substratum [8,25]. In M2 cells, intracellular solvent
ﬂow drives blebs formation and (re)-expression of exogenous FlnA
facilitates actin cortical gelation thereby leading to decreased size and
occurrence of the blebs [8]. These observations were consistent with
the many studies which, thereafter, highlighted the role of ﬁlamin A
in cortical actin network organization and stabilization [1–3]. Because,
in their original work, Cunningham and colleagues revealed the critical
role of themolar FlnA to actin ratio to fully suppress bleb formation and
restore M2 cell locomotion, in the present study we a) selected clones
with FlnA/actin molar ratios similar to that of the original FlnA–WT
expressing cell line (A7) (Fig. 1B) and b) established new FlnA–WT to
evaluate possible bias linked to the expression vector and the transfec-
tion protocol used. Our data showed that FlnA–WT clones established
AB
Fig. 5. Rac1 andRhoAGTPases activities aremodiﬁed in FlnA–P637Q cells. A. Representative experiment of active Rac1 pull downusingGST–Crib (left-hand images). Lower Rac1 activity in
FlnA–P637Q cells was quantiﬁed in ﬁve experiments. Themean data are shown on the graph, n = 4, Error bars show SEM, *P b 0.05. B. Increased RhoA activity was detected in FlnA–P637Q
cells (left-hand images). Mean data from ﬁve experiments is shown on the graph, Error bars show SEM, **P b 0.01 versus FlnA–WT cells.
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Interestingly, FlnA–G288R and P637Q expression also suppressed bleb
formation. Together with the absence of any sign of increased protein
degradation (not shown) or changes in subcellular localization of mu-
tant FlnAs (Fig. 2) our data indicate that the twomutations donot gross-
ly affect FlnA structure and FlnA–actin interaction. This idea is
consistent with the location of the mutations in Igl repeats 1 and 4 of
FlnA (for G288R and P637Q, respectively) which are structurally sepa-
rated from the N-terminal actin binding domain by a hinge and the Igl
repeat 9–15 region that constitutes a secondary interaction domain
necessary for high avidity binding to F-actin [2,28].
Although physical FlnA–actin interactions are not drastically altered
by the mutations, the latter impacted cell spreading and locomotion.
Cell migration is known to critically rely on actin cytoskeleton remodel-
ing andmany previous studies established the key role of small GTPases
Rac1 and RhoA in this process [29,30]. According to a simplistic model,
Rac1 is activated at the leading edge of the cells and participates in the
formation of lamellipodia and adhesion complexes and thus to forward
protrusion. On the other hand, RhoA is inhibited at the leading edge but
its activity is then required to stabilize focal adhesion complexes and to
activate contractile events like retraction of trailing cell processes that
are required for migration. Consistent with this model, we showed the
migration-deﬁcient FlnA–P637Q cells exhibited lower Rac1 activity
than FlnA–WT cells. Lower Rac1 activities also ﬁt with the observation
that the FlnA–G288R and P637Q cells are devoid of lamellipodia-like
processes and forward protrusion and they are smaller than FlnA–WT
cells. Functional adhesion assays using xCELLigence system further
corroborated this notion as Rac1 inhibition usingNSC23766 (10 μM) re-
duced FlnA–WT cells adhesion capacities down to those of FlnA–P637Q
and G288R cells. Importantly, similar adhesion defects were also madein another cell model, the HT1080 cells. Because FlnA is known to inter-
act with RhoA and Rac1, one could speculate that the mutations affect
their interactions and thus alter their spatial distribution and regulation.
Althoughwe did not speciﬁcally test mutant-FlnA/GTPases interactions,
we suspect this is unlikely because RhoA and Rac1 interaction domains
on FlnA are located in C-terminal repeats (Igl 21–23) that are remote
from those targeted by the mutations (Igl 1, 4) [30]. Consistent with
RhoA activation being required to release the trailing (caudal) regions
of the cell from substrates we showed the Rho associated kinase
(ROCK) inhibitor (Y27632 10 μM) rescued/stabilized adhesion which
correlated with the induction of large lamellipodia like structures in
FlnA–P637Q cells. Collectively these data are consistent with a mecha-
nism by which the activated RhoA–ROCK signaling cascade suppresses
Rac1 activity resulting in reduced migratory potential.
Mutual antagonism between RhoA and Rac1 GTPases is a well
established mechanism that participates to the spatio-temporal regula-
tion of their activities and the Rac1 speciﬁc GTPase activating protein
FilGAP appeared as an interesting candidate to test. FilGAP is known to
bind FlnA and its phosphorylation by ROCK to increase its Rac1–GAP
activity [22,26]. Indeed, the Rac–GAP activity assays we performed indi-
cated that “active” FilGAP was signiﬁcantly increased in mutant FlnA
cells compared to FlnA–WT cells (N×2). Together with the rescue of
the adhesion of FlnA–P637Q and G288R cells when FilGAP was silenced
our data strongly implicate FilGAP in Rac1 down regulation. Preliminary
co-immunoprecipitation assays indicate that, although the interactions
appeared weaker, mutant FlnAs still bind FilGAP indicating that the
mutations do not drastically impair their physical interactions
(Supplementary data Fig. S2). Preservation of their interaction is actually
consistent with the remote locations of the mutations and FlnA–FilGAP
interaction region on FlnA (Igl repeat 1–4 and 23–24, respectively). On
AB
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Fig. 6. Rac1 and RhoA activities determine FlnA–P637Q and G288R cells spreading. A. FlnA–WT and P637Q cell indexes (CI) measured using xCELLigence system in the presence and ab-
senceof theRac1 inhibitorNSC23766 (10 μM) in FlnA–P637Q (left panel) and theROCK inhibitor Y27632 (10 μM). (right panel). FlnA–WTdata are included inboth panels for comparison.
Results are means ± SEM of four independent experiments. ** indicates signiﬁcant difference between FlnA–WTwith andwithout inhibitors calculated by two-way analysis of variance,
Bonferroni corrected testing (n = 4, $$$P b 0.001 and **P b 0.01). B. Phase contrast images of FlnA–WTand FlnA–P637Q cells seeded on ﬁbronectin coverslip (10 μg/ml) for 2 hours with
or without Y27632 (10 μM). The inhibitor restores lamellipodia like structure in the mutant cells. Scale bar: 20 μm. C. FlnA–WT and G288R cell indexes (CI) measured using xCELLigence
system in the presence and absence of the Rac1 inhibitor NSC23766 (10 μM) in FlnA–P637Q (left panel) and the ROCK inhibitor Y27632 (10 μM) (right panel). FlnA–WTdata are included
in both panels for comparison. Results are means ± SEM of four independent experiments. ** indicates signiﬁcant difference between FlnA–WTwith and without inhibitor calculated by
two-way analysis of variance, Bonferroni corrected testing (n = 4, $$$P b 0.001 and **P b 0.01).
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mechanical stressmay under estimate a potential effect of themutations
on their interaction. In line with the critical role of mechanical strain on
FlnA–FilGAP interaction and the prevalence of shear stress and pressure
during cardiac contraction, increased FilGAP availability resulting from
reduced FlnA–FilGAP interaction might contribute to the pathological
process [31]. Future studies will be required to ascertain this issue.
In an effort to elucidate the mechanisms linking FlnA–G288R and
P637Q mutations to RhoA activation, we investigated FlnA interaction
with R-Ras thatwas recently shown to bind to the Igl 1–8 repeats region
of FlnA [3,9,12]. In addition, Ras effector proteins include guanine nucle-
otide exchange factors and GTPase-activating proteins such as the Rac1
exchange factor Tiam1, and p120RasGAP/p190RhoGAP complex that
couple Ras to RhoA and Rac1 GTPases signaling [32–34]. It was thus
tantalizing to speculate that the mutations located in the proximity ofR-Ras binding site could alter its binding and Rho–GTPases regulation.
However, our preliminary results showed that FlnA–G288R and P637Q
mutations do not modify R-Ras binding suggesting FlnA–Ras interaction
is not critical to the adhesion and migration deﬁciencies we observed
(Supplementary Fig. S3).
Our data support a mechanism by which speciﬁc (N-terminal) FlnA
mutations modify actin remodeling pathways. These pathways are
critical for cellular responses to mechanical stress, cell–extracellular
matrix interactions and epithelial–mesenchymal transformation, three
key processes involved in valve development and homeostasis [35]. In-
terestingly, we recently deﬁned co-operative functional interactions be-
tween serotonin, transglutaminase-2 (TG2) and FlnA in the remodeling
of cardiac valves during valvulogenesis and “TG2/serotonylation”
events participate to actin-remodeling processes and increase RhoA
activity [36,37]. Whether small GTPase imbalance and increased RhoA
AB
C
Fig. 7. FilGAP is “activated” and involved in the reduced spreading of FlnA–P637Q and G288R cells. A. Example of FilGAP extinction in FlnA–P637Q cells treatedwith FilGAP SiRNA. The blot
was probedwith anti FilGAP andGAPDH (to control loading, 25 μg). B. Cell index of FlnA–P637Q andG288R cells treatedwith control and FilGAP SiRNA (left and right panels respectively).
FlnA–WTdata are included in both panels for comparison. Results aremeans ± SEM of four independent experiments (n = 4Error bars show SEM, **P b 0.01.) C. Rac1–GAP activity pull
down assay. FlnA–WT, G288R and P637Q melanoma cells were transfected with FilGAP-HA (input lower blot) and “active” FilGAP pulled down using GST–Rac1–Q61L fusion protein
(upper blot). “Active” FilGAP pulled down in mutant FlnA cells more than doubled with respect to FlnA–WT cells. **P b 0.01 versus FlnA–WT cells (n = 4).
333D. Duval et al. / Biochimica et Biophysica Acta 1843 (2014) 234–244serotonylation contribute to valve development and valvular dystrophy
remains to be determined [38] but points to candidate therapeutic
mechanisms for human heart valve diseases.
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